Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J van Rossum

Showing results (111-120 of 147) with videos related to

Pageof 15
Sort By:
Pediatric Rheumatology Online Journal|February 8, 2017
A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-studyP C E Hissink Muller, D M C Brinkman, D Schonenberg, et al.
Breast Care (Basel, Switzerland)|January 28, 2022
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, et al.
RMD Open|March 17, 2023
Patterns of clinical joint inflammation in juvenile idiopathic arthritisSascha L Heckert, Petra C E Hissink-Muller, J Merlijn van den Berg, et al.
Arthritis Care & Research|March 2, 2010
Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritisH M Albers, D M C Brinkman, S S M Kamphuis, et al.
Annals of the Rheumatic Diseases|September 14, 2004
Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidityI M De Kleer, D M C Brinkman, A Ferster, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
Annals of the Rheumatic Diseases|May 11, 2007
Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatmentMarion A J van Rossum, Renée M van Soesbergen, Maarten Boers, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2018
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)A G J van Rossum, M Kok, E van Werkhoven, et al.
Oncotarget|January 27, 2018
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapyAnnelot G J van Rossum, Marleen Kok, Danielle McCool, et al.
Arthritis and Rheumatism|February 1, 2007
Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritisEvelien Zonneveld-Huijssoon, Arash Ronaghy, Marion A J Van Rossum, et al.
Pageof 15

Showing results (111-120 of 147) with videos related to

Sort By:
Pageof 15
Pediatric Rheumatology Online Journal|February 8, 2017
A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-studyP C E Hissink Muller, D M C Brinkman, D Schonenberg, et al.
Breast Care (Basel, Switzerland)|January 28, 2022
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, et al.
RMD Open|March 17, 2023
Patterns of clinical joint inflammation in juvenile idiopathic arthritisSascha L Heckert, Petra C E Hissink-Muller, J Merlijn van den Berg, et al.
Arthritis Care & Research|March 2, 2010
Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritisH M Albers, D M C Brinkman, S S M Kamphuis, et al.
Annals of the Rheumatic Diseases|September 14, 2004
Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidityI M De Kleer, D M C Brinkman, A Ferster, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
Annals of the Rheumatic Diseases|May 11, 2007
Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatmentMarion A J van Rossum, Renée M van Soesbergen, Maarten Boers, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2018
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)A G J van Rossum, M Kok, E van Werkhoven, et al.
Oncotarget|January 27, 2018
Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapyAnnelot G J van Rossum, Marleen Kok, Danielle McCool, et al.
Arthritis and Rheumatism|February 1, 2007
Safety and efficacy of meningococcal c vaccination in juvenile idiopathic arthritisEvelien Zonneveld-Huijssoon, Arash Ronaghy, Marion A J Van Rossum, et al.
Pageof 15